89bio, Inc.
ETNB
$8.26
$0.010.12%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.61M | 7.93M | 7.21M | 6.22M | 6.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.21M | 39.35M | 42.13M | 28.52M | 25.36M |
| Operating Income | -41.21M | -39.35M | -42.13M | -28.52M | -25.36M |
| Income Before Tax | -36.37M | -34.73M | -38.39M | -28.84M | -24.59M |
| Income Tax Expenses | 3.87M | -- | -- | -- | 16.00K |
| Earnings from Continuing Operations | -40.24M | -34.73M | -38.39M | -28.84M | -24.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.24M | -34.73M | -38.39M | -28.84M | -24.60M |
| EBIT | -41.21M | -39.35M | -42.13M | -28.52M | -25.36M |
| EBITDA | -41.19M | -39.34M | -42.12M | -28.51M | -25.35M |
| EPS Basic | -0.50 | -0.45 | -0.52 | -0.54 | -0.48 |
| Normalized Basic EPS | -0.30 | -0.28 | -0.32 | -0.35 | -0.31 |
| EPS Diluted | -0.50 | -0.45 | -0.52 | -0.54 | -0.48 |
| Normalized Diluted EPS | -0.30 | -0.28 | -0.32 | -0.35 | -0.31 |
| Average Basic Shares Outstanding | 80.70M | 76.34M | 74.13M | 53.17M | 50.81M |
| Average Diluted Shares Outstanding | 80.70M | 76.34M | 74.13M | 53.17M | 50.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
